Literature DB >> 3118798

In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

J A Bosso1, B A Saxon, J M Matsen.   

Abstract

The in vitro activity of aztreonam combined with tobramycin and with gentamicin was assessed in 78 clinical isolates of Pseudomonas aeruginosa and 11 clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Synergy was detected in 56.4% of P. aeruginosa isolates and 60% of P. cepacia isolates with the aztreonam-tobramycin combination and in 49.3% of P. aeruginosa isolates and 81.8% of P. cepacia isolates with the aztreonam-gentamicin combination. No antagonism was observed. These combinations merit clinical evaluation in the treatment of patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3118798      PMCID: PMC174950          DOI: 10.1128/AAC.31.9.1403

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections.

Authors:  M I Marks; R Prentice; R Swarson; E K Cotton; T C Eickhoff
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

2.  Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.

Authors:  B Friis
Journal:  Scand J Infect Dis       Date:  1979

3.  Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  A S Prince; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

4.  Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin.

Authors:  M F Parry; H C Neu; M Merlino; P F Gaerlan; C N Ores; C R Denning
Journal:  J Pediatr       Date:  1977-01       Impact factor: 4.406

5.  Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  H Michalsen; T Bergan
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

6.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

Authors:  F J McLaughlin; W J Matthews; D J Strieder; B Sullivan; A Taneja; P Murphy; D A Goldmann
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

8.  Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis.

Authors:  H Michalsen; T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1981

9.  Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

Authors:  N E Møller; N Høiby
Journal:  Scand J Infect Dis Suppl       Date:  1981

10.  In vitro activity of azthreonam, a monobactam antibiotic.

Authors:  N V Jacobus; M C Ferreira; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

View more
  7 in total

Review 1.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

2.  Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.

Authors:  J A Bosso; J E Allen; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

3.  Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability.

Authors:  J L Burns; L A Hedin; D M Lien
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

5.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

6.  Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia.

Authors:  J L Burns; D M Lien; L A Hedin
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 7.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.